These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2779590

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 4. [Variance in effects of subthalamic nucleus stimulation].
    Okiyama R, Yokochi F, Taniguchi M, Takahashi H, Hasegawa N, Hamada I.
    No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577
    [Abstract] [Full Text] [Related]

  • 5. [Dyskinesia caused by L-DOPA].
    Derkinderen P, Vidailhet M.
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [Abstract] [Full Text] [Related]

  • 6. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M.
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L, Bracco F, Saladini M.
    J Neural Transm Suppl; 1986 Feb; 22():201-7. PubMed ID: 3465871
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG, Scorticati MC, Micheli FE.
    Medicina (B Aires); 2000 Feb; 60(3):321-5. PubMed ID: 11050808
    [Abstract] [Full Text] [Related]

  • 11. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M, Nicoletti A, Muñoz-S D, Tapia-Núñez J.
    Rev Neurol; 2000 Feb; 49(1):33-40. PubMed ID: 19557698
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The spectrum of levodopa-induced dyskinesias.
    Fahn S.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [Abstract] [Full Text] [Related]

  • 15. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
    Pantelatos A, Fornadi F.
    Adv Neurol; 1993 Apr; 60():690-7. PubMed ID: 8420212
    [Abstract] [Full Text] [Related]

  • 16. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1994 May; 24(1):12-21. PubMed ID: 8147565
    [Abstract] [Full Text] [Related]

  • 19. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.